Announcements Trials
Browse Landscape

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 7INDUSTRY 2

Study Type

Interventional 6Observational 2

Sponsor

Conditions

Inflammatory Bowel Diseases 1Crohn Disease 1Colitis, Ulcerative 1Arthritis, Rheumatoid 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Infliximab × Clear all
NCT03452501 2021-02-23

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

Hikma Pharmaceuticals LLC

Completed
157 enrolled

Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases

NCT00724672 2015-06-01

A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)

Merck Sharp & Dohme LLC

Withdrawn

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡